These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31416335)

  • 1. Doravirine: A Return of the NNRTI Class?
    Blevins SR; Hester EK; Chastain DB; Cluck DB
    Ann Pharmacother; 2020 Jan; 54(1):64-74. PubMed ID: 31416335
    [No Abstract]   [Full Text] [Related]  

  • 2. Doravirine: a review.
    Colombier MA; Molina JM
    Curr Opin HIV AIDS; 2018 Jul; 13(4):308-314. PubMed ID: 29794817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
    Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
    Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
    Boyle A; Moss CE; Marzolini C; Khoo S
    Clin Pharmacokinet; 2019 Dec; 58(12):1553-1565. PubMed ID: 31388941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
    Talwani R; Temesgen Z
    Drugs Today (Barc); 2020 Feb; 56(2):113-124. PubMed ID: 32163527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational Design of Doravirine: From Bench to Patients.
    Hwang C; Lai MT; Hazuda D
    ACS Infect Dis; 2020 Jan; 6(1):64-73. PubMed ID: 31621289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
    Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Rodgers A; Lupinacci L; Kumar S; Sklar P; Hanna GJ; Hwang C; Martin EA;
    Lancet HIV; 2020 Jan; 7(1):e16-e26. PubMed ID: 31740348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
    Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Xu X; Rodgers A; Lupinacci L; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C;
    Lancet HIV; 2018 May; 5(5):e211-e220. PubMed ID: 29592840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doravirine: First Global Approval.
    Deeks ED
    Drugs; 2018 Oct; 78(15):1643-1650. PubMed ID: 30341683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
    Smith SJ; Pauly GT; Akram A; Melody K; Ambrose Z; Schneider JP; Hughes SH
    J Acquir Immune Defic Syndr; 2016 Aug; 72(5):485-91. PubMed ID: 27124362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.
    Martin EA; Lai MT; Ngo W; Feng M; Graham D; Hazuda DJ; Kumar S; Hwang C; Sklar P; Asante-Appiah E
    J Acquir Immune Defic Syndr; 2020 Dec; 85(5):635-642. PubMed ID: 32925358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
    Scheibe K; Urbańska A; Jakubowski P; Hlebowicz M; Bociąga-Jasik M; Raczyńska A; Szymczak A; Szetela B; Łojewski W; Parczewski M
    Antivir Ther; 2021 May; 26(3-5):69-78. PubMed ID: 35485331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of etravirine in combination antiretroviral therapy].
    Domingo P
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doravirine: its role in HIV treatment.
    Stockdale AJ; Khoo S
    Curr Opin HIV AIDS; 2022 Jan; 17(1):4-14. PubMed ID: 34740228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.
    Wong A; Goldstein D; Mallolas J; DeJesus E; Johnson M; Molina JM; Pozniak A; Rodgers A; Teal V; Hepler D; Kumar S; Sklar P; Hanna GJ; Hwang C; Badshah C; Teppler H
    J Acquir Immune Defic Syndr; 2019 Dec; 82(4):e47-e49. PubMed ID: 31425317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of doravirine-based regimen population target in a large Italian clinical center.
    Farinacci D; Ciccullo A; Lombardi F; Moschese D; D'Angelillo A; Iannone V; Lamanna F; Passerotto RA; Giambenedetto SD
    Antivir Ther; 2021 May; 26(3-5):79-83. PubMed ID: 35485330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.
    Gatell JM; Morales-Ramirez JO; Hagins DP; Thompson M; Arastéh K; Hoffmann C; Raffi F; Osiyemi O; Dretler R; Harvey C; Xu X; Plettenberg A; Smith DE; Portilla J; Rugina S; Kumar S; Frobose C; Wan H; Rodgers A; Hwang C; Teppler H
    Antivir Ther; 2019; 24(6):425-435. PubMed ID: 31355775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment.
    Wang Y; De Clercq E; Li G
    Expert Opin Drug Metab Toxicol; 2019 Oct; 15(10):813-829. PubMed ID: 31556749
    [No Abstract]   [Full Text] [Related]  

  • 20. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.